ERBB2 c.152A>G ;(p.Q51R)

Variant ID: 17-37863321-A-G

NM_004448.2(ERBB2):c.152A>G;(p.Q51R)

This variant was identified in 2 publications

View GRCh38 version.




Publications:


The clinicopathological study of lung cancer concealed in end-stage of interstitial lung disease.

Translational Cancer Research
Wang, Bei B; Zhang, Xiaoyan X; Chen, Huang H; Yang, Lei L; Li, Jie J; Xiao, Fei F; Liang, Chaoyang C; Zhong, Dingrong D
Publication Date: 2020-02

Variant appearance in text: HER2: Q51R
PubMed Link: 35117398
Variant Present in the following documents:
  • Main text
  • tcr-09-02-536.pdf
View BVdb publication page



Proteogenomics Reveals Perturbed Signaling Networks in Malignant Melanoma Cells Resistant to BRAF Inhibition.

Molecular & Cellular Proteomics : Mcp
Schmitt, Marisa M; Sinnberg, Tobias T; Bratl, Katrin K; Zittlau, Katharina K; Garbe, Claus C; Macek, Boris B; Nalpas, Nicolas C NC
Publication Date: 2021-10-19

Variant appearance in text: ERBB2: Q51R
PubMed Link: 34673281
Variant Present in the following documents:
  • mmc2.xlsx, sheet 11
View BVdb publication page



Proteogenomics Reveals Perturbed Signaling Networks in Malignant Melanoma Cells Resistant to BRAF Inhibition.

Molecular & Cellular Proteomics : Mcp
Schmitt, Marisa M; Sinnberg, Tobias T; Bratl, Katrin K; Zittlau, Katharina K; Garbe, Claus C; Macek, Boris B; Nalpas, Nicolas C NC
Publication Date: 2021

Variant appearance in text: ERBB2: Q51R
PubMed Link: 34673281
Variant Present in the following documents:
  • mmc2.xlsx, sheet 11
View BVdb publication page